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The adrenergic system is a part of autonomic
nervous system, which regulates neuronal,
endocrine, metabolic and cardiovascular function.
Adrenergic receptors (ARs), the members of G-pro-
tein coupled receptors (GPCRs) superfamily, are
divided into three main classes α1, α2 and β (1). ARs
of α2 are a heterogeneous population, and at present
three different subtypes α2A-α2C have been identified
by molecular cloning in both the human and rat
species. All three subtypes of α2-ARs have been
shown to inhibit the activation of adenylate cyclase
and thus reduce the levels of cAMP (2, 3). The α2A
and α2C subtypes are found mainly in the central
nervous system (4). Stimulation of these receptor
subtypes may be responsible for sedation, analgesia,
and sympatholytic effects. The αB-AR are found
more frequently on vascular smooth muscle and
have been shown to mediate vasopressor effects. All
three α2-AR subtypes represent potential cardiovas-
cular drug targets and agonists of α2-AR have been
used for decades to treat common medical condi-
tions such as hypertension; attention-deficit/hyper-
activity disorder; various pain and panic disorders;
symptoms of opioid, benzodiazepine, and alcohol
withdrawal; and cigarette craving (5). Activation of
α2C-AR might have beneficial sympatho-inhibitory
effects in hypertension and heart failure without the
sedative side effects accompanying current cloni-
dine-like drugs (6-8). 
Compounds that are either agonists or antago-
nists of α2-ARs have been discovered that represent
a broad spectrum of chemical classes. Within these,
a great range of selectivity has been demonstrated
by physiologic and radioligand binding experi-
ments. One of the most widely studied classes of α2-
AR ligands are the imidazolines (9, 10), which have
been shown to be very peculiar in that small struc-
tural modifications can alter the balance between
agonist and antagonist, as well as the α1/α2 selectiv-
ity. Representative examples of the most important
structural types of α2-AR -selective agonists and
antagonists are shown in Figure 1. 
On the other hand, platelet activation is a key
factor in arterial thrombosis and antiplatelet therapy
remains crucial in the therapeutic strategy for patients
with cardiovascular diseases and high risk for a future
EVALUATION OF ANTIPLATELET ACTIVITY OF NOVEL GUANIDINE
DERIVATIVES IN THE ASPECTS OF THEIR ADRENERGIC 
RECEPTOR ACTIVITY
AGNIESZKA ZAG”RSKA1*, MONIKA MARCINKOWSKA1, JOANNA åNIECIKOWSKA1, 
ADAM BUCKI1, AGATA SIWEK2, MONIKA KUBACKA3, GRZEGORZ KAZEK4, JACEK SAPA3,
MAGDALENA KOTA—SKA3 and MARCIN KO£ACZKOWSKI1
1Department of Medicinal Chemistry, 2Department of Pharmacobiology, 3Department of Pharmacodynamics,
4Department of Pharmacological Screening, Chair of Pharmacodynamics, 
Jagiellonian University Medical College, 9 Medyczna Street, 30-688 KrakÛw, Poland
Abstract: Designed acetamide derivatives based on guanidine and various heteroaryl carboxylic acids, were
preliminary in vitro study of their adrenergic receptor affinity and anti-plateled effects. The obtained results
have showed that exchange of 2,6-dichloro-phenyl substituent of guanidine into heteroaryl moieties, caused the
decrease of receptor affinity, especially for α1-adrenoceptors. The observed receptor profile of activity for α2B-
AR was not changed compared to α1-ARs. Moreover, the observed effects on platelet aggregation induced by
sub-threshold concentration of collagen and adrenaline strongly suggested that antiaggregant effect of N-
(diaminomethylene)-2-(pyridin-3-yl)acetamide and N-(diaminomethylene)-2-(pyridin-4-yl)acetamide depends
on their α2B-ARs antagonistic activity. 
Keywords: guanidine, α1-adrenoceptors, α2B-adrenoceptors, anti-aggregation, anti-platelet effects
525
* Corresponding author: e-mail: agnieszka.zagorska@uj.edu.pl
526 AGNIESZKA ZAG”RSKA et al.
cardiovascular event. Although controlled plug for-
mation is necessary for the prevention of excessive
blood loss, there are many pathological conditions in
which the formation of occlusive thrombi may occur
leading to severe clinical complications, including
myocardial infarction and ischemic stroke (11, 12).
Activation of sympathetic nervous system is also
involved in the pathogenesis of thrombosis (11).
Moreover, there were evidences that adrenaline has
direct effects on platelets that are not mediated by
ADP, endoperoxides or thromboxane A2 liberated
from platelets (13). It induces primary platelet aggre-
gation, potentiation of stimulus-induced aggregation
and secretion and inhibition of adenylate cyclase
through activation of α2-AR (14). The experiments of
Steen et al. (15) proved that adrenaline per se does not
induce human platelet activation in vitro. The platelet-
stimulating effect of adrenaline through α2-AR
requires simultaneous activation by a true stimulatory
platelet agonist. However, recent study indicated that
α2B-ARs exists in platelets and adrenaline induced
amplification of platelet aggregation is at least in part
mediated by activation of these receptors (11).
The aims of presented study were synthesis of
designed acetamide derivatives based on guanidine
and various heteroaryl carboxylic acids, and prelim-
inary in vitro study of their adrenergic receptor affin-
ity and anti-plateled effects. The assumption was to
find anti-aggregation agents and eliminate side-
effects on the cardiovascular system. The design of
the new compounds using molecular modeling tools
was carried out to introduce into structure of α2A-AR
agonist substituents maintaining high affinity and
selectivity for α2B-AR. Moreover, the studies were
focused on compounds that the least possible affect-
ed on α1-AR and penetrated the blood-brain barrier.
EXPERIMENTAL
Chemistry
Structures of the investigated compounds (3a-
3e) and their syntheses are presented in Scheme 1.
Compounds 3a-3d were obtained by path A
(Scheme 1) within a reaction of condensation of cor-
responding ethyl aryl-acetate (1a-d) with guanidine
hydrochloride in isopropanol. Corresponding ethyl
aryl-acetate derivatives (1a-d) were obtained
according to the standard Fischer esterification pro-
cedure. Compound 3e was obtained by path B
(Scheme 1), by direct preparation of primary amides
from carboxylic acid and guanidine hydrochloride
using imidazole under microwave irradiation (16).
The structure elucidations of the newly synthesized
compounds were carried out using different spectro-
scopic techniques including 1H and 13C NMR and
LC/MS. Further confirmations of the compounds
were carried out by elemental analysis (± 0.4%).
The elemental analysis data and some physical prop-
erties of these compounds are reported in the exper-
imental part.
All the chemicals used were commercial prod-
ucts employed without purification. Purity of the
synthesized compounds was confirmed by TLC per-
formed on Merck silica gel 60 F254 aluminum sheets
(Merck, Darmstadt, Germany) with the following
solvents: A: dichloromethane/methanol (90 : 10), B:
diethyl ether/dichloromethane/n-hexane/methanol
(40 : 38: 20 : 0.2), C: dichloromethane/methanol/
ammonia solution 25% (80 : 20 : 0.1). Spots were
detected by their absorption under UV light (λ = 254
nm). Column chromatography separations were car-
ried out on column with Merck Kieselgel 60 using
the solvents A-C. 1H and 13C NMR were recorded at
300 MHz with Varian Mercury-VX spectrometer, in
CDCl3 or DMSO-d6 solutions, using TMS (δ = 0.00
ppm) as an internal standard. The J values are in
Hertz (Hz), and splitting patterns are designated as
follows: s (singlet) and m (multiplet). LC/MS analy-
ses were performed on Waters Acquity TQD appa-
ratus with eλ DAD detector. For mass spectrometry
ESI+ (electrospray positive) ionization mode was
used. UV spectra were taken in 200-700 nm range.
For establishing the purity of compounds, UV chro-
matograms were used. All investigated final com-
pounds had purity over 95%. The LC/MS system
consisted of a Waters Acquity UPLC, coupled to
Figure 1. Chemical structures of potent α2-AR ligands
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Waters TQD mass spectrometer (electrospray ion-
ization mode ESI-tandem quadrupole). All analyses
were carried out using an Acquity UPLC BEH C18,
50 × 2.1 mm reversed-phase column. LC/MS data
were obtained by scanning the first quadrupole in
0.5 s in a mass range from 100 to 700 m/z; 8 scans
were summed up to produce the final spectrum.
Elemental analyses were found within ±0.4% of the
theoretical values. Reactions under microwave irra-
diation were carried out using a Discover LabMate
(CEM Corporation). All products were isolated as
water soluble hydrochloride salts (crystallizing
oils).
General procedures for preparation of final com-
pounds (3a-3d)
Mixtures of corresponding ethyl aryl-acetate
(1a-d) (1 mM) with guanidine hydrochloride (1.1
mM) in isopropanol, were heated under reflux
(60OC) for 72 h. After evaporation of the solvent to
the brown oil residues, products were separated by
column chromatography. 
N-(Diaminomethylene)-2-(pyridin-3-yl)acetami-
de hydrochloride (3a)
From 1a in 60% yield; Rf = 0.61 (A); 1H-NMR
(CDCl3, δ, ppm): 8.82-8.71 (m, 1H), 8.52-8.44 (m,
1H), 7.81-7.75 (m, 1H), 7.31-7.04 (s, 5H), 2.48 (s,
2H). 13C NMR (DSMO-d6, δ, ppm): 158.77, 153.98,
146.15, 141.35, 128.20, 124.83, 39.43; ESI-MS
(m/z) 180.19 (M+H)+. Analysis: calcd. for
C8H11ClN4O: C, 44.88; H, 5.17; N, 26.17%; found:
C, 44.64; H, 5.36; N, 26.14%.
N-(Diaminomethylene)-2-(pyridin-4-yl)acetami-
de hydrochloride (3b)
From 1b in 60% yield; Rf = 0.89 (B) 1H NMR:
(CDCl3, δ, ppm): 8.51 (br. s., 4 H), 7.63 (dd, J = 1.8,
8.0 Hz, 2 H), 7.33 ñ 7.18 (m, 2 H), 3.63 ñ 3.56 (m,
2 H) 13C NMR (DSMO-d6, δ, ppm): 158.77, 153.98,
146.15, 141.35, 128.20, 124.83, 39.43; LC/MS m/z
calcd.: 178.19 , found: 180.04 (M+2H)+. Analysis:
calcd. for C8H11ClN4O: C, 44.76; H, 5.17; N,
26.10%; found C, 44.62; H, 5.38; N, 26.08%. 
N-(Diaminomethylene)-2-(pyrazin-2-yl)acetami-
de hydrochloride (3c)
From 1c in 51% yield; Rf = 0.90 (B);1H-NMR
(CDCl3, δ, ppm): 8.79-8.72 (m, 5H), 8.59-8.51 (m,
2H), 3.94 (s, 2H), 13C NMR (DSMO-d6, δ, ppm):
169.36, 150.98, 144.61, 144.37, 142.06, 41.0; ESI-
MS (m/z) 181.19 (M+H)+. Analysis: calcd for
C7H10ClN5O: C, 40.37; H, 4.67%; N, 32.64%;
found: C, 40.24; H, 4.63; N, 32.54%.
Scheme 1. Synthetic pathways of novel acetamide hydrochlorides (3a-3e)
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N-(Diaminomethylene)-2-(2,3-dihydrobenzo[b]
[1,4]dioxiny-6-yl)acetamide hydrochloride (3d)
From 1d in 76% yield; Rf = 0.87 (C); 1H-NMR
(CDCl3, δ, ppm): 7.3 (s, 4H), 6.81-6.73 (m, 3H),
4.25 (s, 4H), 3.52 (s, 2H); 13C NMR (DSMO-d6, δ,
ppm): 171.73, 143.38, 142.64, 127.26, 122.19,
118.03, 117.24, 64.30, 60.80, 40.63; ESI-MS (m/z)
237.16 (M+H)+. Analysis: calcd for C11H14ClN3O3:
C, 48.62; H, 5.19; N, 15.46%; found: C, 48.56; H,
5.30; N, 15.54%.
N-(Diaminomethylene)-2-(4-(dimethylamino)
phenyl)acetamide hydrochloride (3e)
The mixture of N-(diaminomethylene)-2-(4-
(dimethylamino)phenyl carboxylic acid 2 (1 mM),
guanidine hydrochloride (2 mM) and imidazole (1
mM) was exposed to microwave irradiation with
solvent free condition (100OC), power of MW oven
(200 W) for 1 h (in 15 min intervals). The resulting
crude product (3e) extracted was purified by column
chromatography using solvents A system. 
Yield 21%; Rf = 0.87 (C);1H-NMR (CDCl3, δ,
ppm): 8.83-8.71 (m, 5H), 8.67-8.52 (m, 3H), 3.94 (s,
2H), 3.24 (s, 6H), 13C NMR (DSMO-d6, δ, ppm):
169.36, 150.98, 144.61, 144.37, 142.06, 134.6,
132.1, 114.9, 110.3, 41.0; ESI-MS (m/z) 221.27
(M+H)+. Analysis: calcd for C11H17ClN4O0: C,
51.45; H, 6.67; N, 21.82%; found: C, 51.24; H, 6.63;
N, 21.74%.
Pharmacology
In vitro binding assay 
Determination of the affinity of the tested com-
pounds at the adrenoceptors
The affinity of the obtained compounds (3a-
3e) was evaluated by radioligand binding assays
(the ability to displace [3H]-prazosin (spec. act. 85
Ci/mM, α1 adrenergic receptor), [3H]-clonidine
(spec. act. 70.5 Ci/mM, Perkin Elmer, α2 adrener-
gic receptor)) on rat cerebral cortex. The brains
were homogenized in 20 volumes of an ice-cold 50
mM Tris-HCl buffer (pH 7.6) using an Ultra
Turrax T25B (IKA) homogenizer and were cen-
trifuged at 20 000 × g (15 048 rpm) for 20 min (0-
4OC). The pellet was resuspended in the same
buffer and centrifuged again. The final incubation
mixture consisted of 240 µL tissue suspension, 30
µL of [3H]-prazosin (0.2 nM) or [3H]-clonidine (2.0
nM) solution and 30 µL of the buffer containing the
investigated compounds. The concentrations of
analyzed compounds ranged from 10-10 to 10-5 M.
For measuring the unspecific binding, 10 µM phen-
tolamine (in the case of [3H]-prazosin) or 10 µM
clonidine (in the case of [3H]-clonidine) were
applied. The following incubation parameters were
applied: 30OC for 30 min (α1 receptor) and 30OC for
25 min (α2 receptor). The incubation was terminat-
ed by rapid filtration over glass fiber filters
FilterMate B (PerkinElmer, USA) using 96-well
FilterMate harvester (PerkinElmer, USA). Five
rapid washes were performed with ice-cold 50 mM
Tris-HCl buffer, pH 7.6. Filter mate was dried in
microwave and placed in plastic bag (PerkinElmer,
USA) and soaked in 10 mL of liquid scintillation
cocktail Ultima Gold MV (PerkinElmer, USA).
After even distribution of scintillation cocktail fil-
ter bag was sealed. The radioactivity on the filter
was measured in MicroBetaTriLux 1450 scintilla-
tion counter (PerkinElmer, USA). All the assays
were made in duplicate. Radioligand binding data
were analyzed using iterative curve fitting routines
GraphPad Prism 4.0 (GraphPad Software) using
the built-in three parameter logistic model describ-
ing ligand competition binding to radioligand-
labeled sites. The log IC50 (i.e., the log of the lig-
and concentration that reduces specific radioligand
binding by 50%) estimated from the data is used to
obtain the Ki by applying the Cheng-Prusoff
approximation.
Functional assays for α2B-adrenoceptors
Test and reference compounds were dissolved
in dimethyl sulfoxide (DMSO) at a concentration of
1 mM. Serial dilutions were prepared in 96-well
microplate in assay buffer and 8 to 10 concentra-
tions were tested.
A cellular aequorin-based functional assay was
performed with recombinant CHO-K1 cells express-
ing mitochondrially targeted aequorin, human
GPCR for α2B receptors. After thawing, cells were
transferred to assay buffer (DMEM/HAMís F12
with 0.1% protease free BSA) and centrifuged. The
cell pellet was resuspended in assay buffer and coe-
lenterazine h was added at final concentrations of 5
µM. The cells suspension was incubated at 16OC,
protected from light with constant agitation for 16 h
and then diluted with assay buffer to the concentra-
tion of 100 000 cells/mL. After 1 h of incubation, 50
µL of the cells suspension was dispensed using auto-
matic injectors built into the radiometric and lumi-
nescence plate counter MicroBeta2 LumiJET
(PerkinElmer, USA) into white opaque 96-well
microplates preloaded with test compounds.
Immediate light emission generated following calci-
um mobilization was recorded for 30 s. In antagonist
mode, after 30 min of incubation the reference ago-
nist was added to the above assay mix and light
emission was recorded again. Final concentration of
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the reference agonist was equal to EC80 (1.6 µM
oxymetazoline).
Whole blood aggregation test 
In vitro aggregation tests were conducted using
freshly collected whole blood with Multiplate
platelet function analyzer (Roche Diagnostic), the
five-channel aggregometer based on measurements
of electric impedance. The Multiplate analyzer
allows the duplicate measurement with dual elec-
trode probes. Blood was drawn from carotid of rats
with hirudin blood tube (Roche Diagnostic). 300 µL
of hirudin anticoagulated blood was mixed with 300
µL prewarmed isotonic saline solution containing
studied compound in DMSO or vehicle (DMSO
0.1% final) and preincubated for 3 min at 37OC with
continuous stirring. The agonists (ADPtest,
COLtest, Roche Diagnostic) were diluted using
deionized water. Aggregation was induced by
adding collagen (final concentration 1.6 µg/mL), or
adrenaline and subthreshold concentration of colla-
gen (final concentration 50 µM + 0.9 µg/mL).
Activated platelet function was recorded for 6 min.
The Multiplate software analyzed the area under the
curve of the clotting process of each measurement
and calculated the mean values.
Data were presented as the mean ± SEM.
Statistical comparisons were made by the analysis of
variance (ANOVA) and significance of the differ-
ences between control group and treated groups was
determined by Dunnet post hoc test. p < 0.05 was
considered significant. 
RESULTS AND DISCUSSION
The preparation of a novel group of molecules
was carried out in a multistep reaction synthesis as
shown in Scheme 1. The specific properties of the
guanidine, causing inefficiency standard methods
for amide bond formation. Guanidine is an excep-
tion to the general rule, when the fatty amines are
less basic than amines saturated (pKa = 13.6).
Guanidine cation is formed in a polar solvent after
the adoption of a proton from it, this form is more
stable than the free base of guanidine. Therefore,
optimization the synthetic method resulting various
conditions (path A and B) for synthesis of com-
pounds 3a-3e. Compounds 3a-3d were obtained by
path A (Scheme 1) within a reaction of condensation
of corresponding ethyl aryl-acetate (1a-d) with
guanidine hydrochloride in isopropanol. Standard
Fischer esterification (17) procedure was adopted
for synthesis of ethyl aryl-acetate derivatives (1a-d).
The corresponding carboxylic acid and an ethyl
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alcohol were refluxed in the presence of an acid cat-
alyst (hydrogen chloride gas). Compound 3e was
obtained by direct preparation of primary amides
under microwave irradiation from carboxylic acid
and guanidine hydrochloride. 
The affinities of the newly prepared compounds
were evaluated using radioligand binding assays (the
ability to displace [3H]-prazosin and [3H]-clonidine
from α1-AR and α2-AR, respectively) in rat cerebral
cortex (18, 19). The majority of compounds tested
not displaced [3H]-prazosin and [3H]-clonidine from
cortical binding sites. The compounds were also test-
ed in intrinsic activity studies using the human adren-
ergic α2B-adrenoceptor expressed in CHO-K1 cells.
Compounds 3a and 3b were found to be weak antag-
onist of α2B-adrenoceptors (IC50 = 811 and 320 nM),
whereas 3c and 3d have been found as very weak lig-
ands (IC50 = 1487 and 1216 nM). Binding data are
summarized in Table 1. The aims of this project was
synthesis and evaluation of designed acetamide
derivatives based on guanidine and various het-
eroaryl carboxylic acids. In order to achieve the
desired property, 2,6-dichloro-phenyl substituent of
guanidine was replaced with various heteroaryl moi-
eties. Such modification, caused a significant decline
in receptor affinity, especially for α1 receptors. From
the other hand, introduction of heteroaryl moieties
did not change profile of functional activity towards
Figure 2. Effects of studied compounds on whole rat blood aggregation in vitro induced by collagen (1.6 µg/mL). Results are expressed as
the mean ± S.E.M, n = 3, ***p < 0.001 versus control group (0.1% DMSO in saline)
Figure 3. Effects of studied compounds on whole rat blood aggregation in vitro induced by simultaneous addition of adrenaline and colla-
gen (30 µM + 0.9 µg/mL). Results are expressed as the mean ± S.E.M, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 versus control group
(0.1% DMSO in saline)
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α2B adrenergic receptors, and compounds were active
as receptor antagonists. Interestingly, the most active
were compounds with pyridinyl moiety but connect-
ed with N-(diaminomethylene)acetyl fragment in
different position of heterocyclic system (3a and 3b).
N-(Diaminomethylene)-2-(pyridin-4-yl)acetamide
(3b) derivative was two more times active as antag-
onist, compared with pyridin-3-yl analog. 
Next, the compounds 3a and 3b were evaluated
for their antiplatelet effects in rat using in vitro
method. Freshly isolated rat whole blood was incu-
bated with tested substances (10-100 µM) or vehicle
(DMSO). The aggregation responses were evaluated
with Multiplate whole blood aggregometer by meas-
uring impedance change. Platelet aggregation was
induced by collagen or sub-threshold concentration of
collagen and adrenaline. Compounds 3a and 3b were
found to inhibit collagen induced platelet aggregation
in vitro at the concentration of 100 µM, attenuating
platelet aggregation by 83.3% and 61%, respectively
(Fig. 2). Compounds were also tested in a model of
adrenaline mediated amplification of collagen stimu-
lated aggregation. Collagen at a concentration of 0.9
µg/mL did not aggregate rat blood in vitro, whereas
adrenaline alone did not cause aggregation at any
concentration tested. Combining adrenaline with the
sub-maximal concentration of collagen produced a
maximal aggregation response. Compounds 3a and
3b inhibited also aggregation induced by sub-thresh-
old concentration of collagen and adrenaline (Fig. 3),
reducing it at the concentration of 60 µM by 40.3%
and 33.3%, respectively, and at the concentration of
100 µM by 57% and 49.5%, respectively. 
CONCLUSION
The obtained results have showed that
exchange of 2,6-dichloro-phenyl substituent of
guanidine into heteroaryl moieties, caused the
decrease of receptor affinity, especially for α1-
adrenoceptors. The observed receptor profile of
activity for α2B-AR was not changed compared to
α1-ARs. Moreover, the observed effects on platelet
aggregation induced by sub-threshold concentration
of collagen and adrenaline strongly suggested that
antiaggregant effect of N-(diaminomethylene)-2-
(pyridin-3-yl)acetamide and N-(diaminomethyl-
ene)-2-(pyridin-4-yl)acetamide depends on their
α2B-ARs antagonistic activity. 
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